All Oncology News

Approximately one-third of cases of oropharyngeal cancer carried antibodies to one of the driver proteins from HPV16, and those antibodies could be detected more than 10 years prior to the diagnosis of the cancer.

More is now known about the types of HPV that increase risk.

A phase II study has found that denosumab was able to halt progression in the vast majority of enrolled patients with giant cell tumor of the bone as well as reducing the need for surgery.

Yes, it's been found there and on other surprising surfaces.

Researchers at the National Cancer Institute have developed a comprehensive analysis of coding variants in nine of the most frequently studied human tumor cell lines in cancer research.

The FDA has approved afatinib, along with a companion diagnostic, to treat patients with metastatic non-small cell lung cancer who express specific types of EGFR mutations.

A new drug application has been submitted for ibrutinib as a therapy for previously treated CLL and MCL after positive results showed high response rates to the drug in two clinical trials.

Standards established by an interprofessional workgroup.

The FDA has granted priority review to a regimen of pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive early-stage breast cancer.

Patients with chronic lymphocytic leukemia and mantle cell lymphoma showed high response rates to therapy with the novel targeted therapy ibrutinib, further solidifying the safety and efficacy of a drug that has proven very promising in early clinical trials.

Patients with previously treated multiple myeloma responded well to therapy with the monoclonal antibody elotuzumab in combination with lenalidomide and low-dose dexamethasone, with a high objective response rate and longer progression-free survival.

Especially helpful for newly diagnosed patients.

After years of varying decisions by lower courts regarding the patents held on a test for genetic mutations associated with breast cancer, the US Supreme Court has ruled that a segment of DNA in isolation is a natural product and not eligible for patent protection.

Treatment with the investigational agent trebananib resulted in a significant reduction in the risk of progression or death in patients with recurrent ovarian cancer, according to a phase III study.

OncLive is proud to announce that Emory University's Nell Hodgson Woodruff School of Nursing has joined its Strategic Alliance Partnership program.

The FDA has rejected a new drug application for tivozanib for the treatment of advanced renal cell carcinoma, recommending an additional clinical trial to address concerns over existing clinical data.

New system hopes to improve toxicity grading accuracy.

Another year, another survivors' day.

The immunomodulatory agent lenalidomide is now approved by the FDA to treat patients with mantle cell lymphoma who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.

The FDA approved both dabrafenib and trametinib for the treatment of patients with metastatic or unresectable melanoma, as well as a companion diagnostic to properly identify the patients exhibiting the mutations that are targeted by these agents.

The FDA has granted priority review to nab-paclitaxel in combination with gemcitabine for the first-line treatment of patients with metastatic pancreatic cancer.

A late-stage trial investigating inotuzumab ozogamicin as a treatment for patients with aggressive non-Hodgkin lymphoma has been halted after interim data showed the agent was unlikely to improve survival.

This article summarizes 4 abstracts that will be discussed at the 49th Annual ASCO Meeting, focused on the treatment of patients with head and neck cancer.

A new measure of tumor heterogeneity in patients with head and neck squamous cell carcinoma (HNSCC) was significantly associated with tumor progression and adverse treatment outcomes.

New resource provides mechanism for viewing a hospital's billing track record.

A high-profile case of a medical decision being based primarily on the results of a genetic test has prompted a national discussion on the benefits and risks associated with acting on the results of such a test.

The FDA approved radium RA 223 dichloride for the treatment of symptomatic metastatic castration-resistant prostate cancer that has spread to the bones but not to any other organs.

The FDA concurrently approved erlotinib along with a companion diagnostic to be used together in the first-line treatment of patients with metastatic non-small cell lung cancer harboring a specific EGFR mutation.

Goal of proposed law is to improve patient care and reduce the nursing shortage.

The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.